Government Awards Recognize H. Clifford Lane’s Four Decades of Research Achievements
Wednesday, July 27, 2022
The remarkable career of H. Clifford Lane, M.D., might have gone very differently if a NIH scientist hadn’t accidentally eavesdropped on Dr. Lane’s conversation with a colleague in 1979. After hearing Dr. Lane mention that he had missed the deadline to apply for a position at NIH, the NIH researcher made some calls and discovered a spot there had just opened up — one that was perfect for Dr. Lane, who would spend the ensuing decades conducting life-saving research to understand and combat some of the world’s most dangerous infectious diseases.
Now the Clinical Director at the National Institute for Allergy and Infectious Disease (NIAID), Dr. Lane has been named a finalist for the 2022 Samuel J. Heyman Service to America Medals’ Career Achievement Award in recognition of his crucial contributions to the fight against HIV/AIDS, Ebola, COVID-19, and other illnesses. Also known as the “Sammies,” the awards recognize federal employees who are “breaking down barriers, overcoming huge challenges, and getting results.”
Pair Leads Public Health Efforts Focused on Underserved Communities
Monday, November 8, 2021
In the spring of 2020, as the U.S. government implemented public health measures to address the COVID-19 pandemic, it quickly became clear that people in Black, Latino, and American Indian communities were significantly more likely to be hospitalized or die from the new disease than White, non-Hispanic Americans. While the work many scientists did to understand the virus and devise vaccines, diagnostic tests, and treatments made the news regularly, efforts to study and address racial disparities in COVID-19’s impacts were equally important.
When called to lead efforts to shrink those gaps, Gary H. Gibbons, M.D., and Eliseo J. Pérez-Stable, M.D., rose to the challenge. The two IRP investigators, who respectively lead the National Heart, Lung, and Blood Institute (NHLBI) and the National Institute on Minority Health and Health Disparities (NIMHD), helped direct two federal programs dedicated to providing underserved communities with information about, and access to, COVID-19 testing, clinical trials, and vaccines. In recognition of their life-saving work, Drs. Gibbons and Pérez-Stable have been awarded the COVID-19 Response Medal, a special honor bestowed this year as part of the Samuel J. Heyman Service to America Medals. Also known as the “Sammies,” these annual awards recognize and celebrate exceptional work by government employees
Differences in Flu-Fighting Antibodies Could Explain Women’s Greater Susceptibility
Tuesday, September 28, 2021
It is well-known that COVID-19 infections are more often life-threatening in the elderly and individuals with chronic medical conditions like obesity, but the novel coronavirus isn’t the only infectious disease that more severely affects certain groups of people. A new IRP study explored a possible biological reason why women tend to experience worse flu infections and suggests a way to potentially improve the effectiveness of flu vaccines for everyone.
Kizzmekia Corbett and Barney Graham Recognized for Leading IRP Vaccine Research
Monday, July 12, 2021
At the end of 2019, most people were planning for a typical busy year in 2020. The world was looking forward to the Summer Olympics in Japan, the U.S. was deep into election campaigns, and IRP scientists at NIH’s Vaccine Research Center (VRC) were designing vaccines for several coronaviruses in collaboration with a small biotech company called Moderna.
That all changed on a Saturday morning in early January. Chinese scientists had isolated a new coronavirus that was causing a serious epidemic in China’s Wuhan province and released its genetic sequence to the scientific community around the world. Barney Graham, M.D., Ph.D., director of the VRC’s Viral Pathogenesis Laboratory (VPL), and VRC research fellow Kizzmekia Corbett, Ph.D., dropped everything and immediately began working on a vaccine for the illness that would become known as COVID-19.
Vaccine Research Facilitated Rapid Response to Ebola Outbreak
Wednesday, May 26, 2021
IRP Senior Investigator Heinz Feldmann, M.D., was elected to the National Academy of Medicine (NAM) last year for leading the development of the technology that resulted in the first Ebola vaccine approved by the US Food and Drug Administration (FDA) and used by the World Health Organization (WHO) to combat the deadly disease. Election to the NAM is considered one of the highest honors in the fields of health and medicine.
As chief of the Laboratory of Virology at the National Institute of Allergy and Infectious Diseases (NIAID), Dr. Feldmann’s work focuses on viruses like Ebola that cause hemorrhagic fever, a condition marked by fever, weakness, muscle pain, and sometimes bleeding. These highly contagious viruses require specialized laboratories and strict safety procedures to study.
Photos Document NIH Response to COVID-19
Monday, March 15, 2021
This past January marked the one-year anniversary of NIH’s role in addressing COVID-19. For many, it has been a year of hardships and grief, but the race to subdue this new virus has also tapped into the resolve and ingenuity of IRP staff who have already helped create diagnostic tests, vaccines, and therapeutics. Let's take a look back to see a few examples of how IRP scientists and staff have contributed to the fight against COVID-19, as well as how the pandemic has changed life at the NIH.
NIH Scientist’s Decoy Virus Revolutionizes Cervical Cancer Prevention
Monday, March 1, 2021
The National Academy of Sciences (NAS), established in 1863, is comprised of the United States’ most distinguished scientific scholars, including nearly 500 Nobel Prize winners. Members of the NAS are elected by their peers and entrusted with the responsibility of providing independent, objective advice on national matters related to science and technology in an effort to advance innovations in the United States.
IRP senior investigator John T. Schiller, Ph.D., was elected to the NAS in 2020 in recognition of a career that has produced numerous discoveries about human papillomaviruses (HPV), sexually transmitted infections that cause genital warts and are responsible for most cases of cervical cancer. His decades-long partnership with fellow IRP senior investigator Douglas R. Lowy, M.D., who was elected to the NAS in 2009, has yielded a deeper understanding of how HPV infects and damages cells and led to the creation of the first vaccines to prevent HPV infection.
IRP Researcher Nancy Sullivan Led Development of Cutting-Edge Treatment
Wednesday, February 10, 2021
Twenty-four years before the novel coronavirus began spreading in Wuhan, China, an outbreak of another deadly virus burned through the city of Kikwit in what is now the Democratic Republic of Congo. Between January and August of 1995, 316 people are thought to have contracted Ebola, and 252 of them died. More than a decade later, a team of NIH infectious disease scientists would track down one of the survivors and use a sample of the individual’s blood to produce one of the first effective treatments for Ebola.
IRP Investigators Begin Hundreds of New Coronavirus-Related Studies
Monday, June 15, 2020
Within just a few months after COVID-19 began spreading in the United States, IRP researchers had already made numerous important contributions to the fight against the deadly virus. Scientific knowledge about the disease continues to expand at a unprecedented pace, and the IRP will continue to play a major role in this effort over the coming months and years. In fact, nearly 300 new intramural research projects related to the novel coronavirus are currently starting up or have already begun.
IRP Vaccine Research Stretches Back to the NIH’s Birth
Monday, May 18, 2020
Over the past few months, the world has gained a new appreciation for the long, difficult process of producing vaccines as it waits anxiously for one that will provide protection from the novel coronavirus. With the NIH Vaccine Research Center’s efforts to develop a COVID19 vaccine drawing a huge amount of media attention, it is easy to forget that the IRP has been making vital contributions to vaccine development for more than 100 years. These efforts have helped produce vaccinations for smallpox, rubella, hepatitis A, whooping cough, human papillomavirus (HPV), and several other diseases. Read on for a visual journey through the history of IRP vaccine research.